There is a right way and a wrong way to inform a patient about a switch from the reference product to a biosimilar, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Switching from a medication that is working to a biosimilar can make some patients nervous but educated patients feel more confident in the switch, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Transcript
What is the best way to inform a patient that a switch to a biosimilar is happening?
The patients who we've focus grouped and talk to about how they want to be informed, they don't want to receive a letter from their insurance company, stating that “you're being switched.” They really want to have the opportunity to talk to their physician about this change and to be educated. I've been advocating with insurers that they leverage the resources—whether they be the FDA’s resources, whether they be resources like the Crohn's and Colitis Foundation resources, or other organizations that are working to educate their communities about biosimilars.
We know that when patients are educated and have an opportunity to hear from another patient—so the patient storytelling of other patients who have moved from their originator product to a biosimilar—they feel more confident in that. They feel more confident when their physician is educating them and telling them about the switch rather than a form letter sent to them from their insurance company. So, the more we can do this in an engagement way rather than just informing them about a change, the better the outcomes for the patient, the more patients that will be stable on their biosimilar and won't experience the nocebo effect, which we all want to avoid.
If you're needing to educate your patients or even your health care professional community about biosimilars, the Crohn's and Colitis Foundation has numerous resources, including some short format videos that really break down the language of biosimilars, the evidence supporting biosimilars in patient-friendly terms and they're available through our website. And they're less than 5 minutes long, and patients and their caregivers can view them and become more comfortable with the language of biosimilars and understanding how safe and effective they are.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Health Equity and Access Weekly Roundup: May 11, 2024
May 11th 2024This week's topics include frameworks for improving health equity nationwide, addressing social determinants of health, discussing CMS's Medicare rules, investigating breast cancer treatment refusal, and exploring HIV and major depressive disorder in underrepresented groups.
Read More
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More